Pinaverium bromide: Difference between revisions

Page 1
Page 2
Content deleted Content added
CheMoBot (talk | contribs)
Updating {{drugbox}} (changes to watched fields - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wi
+ cite
 
(29 intermediate revisions by 22 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{unreferenced|date=February 2010}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| Watchedfields = changed
| verifiedrevid = 396686449
| verifiedrevid = 448202349
| IUPAC_name = 4-(2-bromo-4,5-dimethoxybenzyl)-4-(2-[2-(6,6-dimethylbicyclo[3.1.1]heptan-2-yl)ethoxy]ethyl)morpholin-4-ium
| IUPAC_name = 4-[(2-Bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium bromide
| image = pinaverium.png
| image = pinaverium bromide.svg


<!--Clinical data-->
<!--Clinical data-->
Line 16: Line 17:
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| legal_status =
| routes_of_administration =
| routes_of_administration =


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
Line 23: Line 24:
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =


<!--Identifiers-->
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 59995-65-2
| CAS_number = 53251-94-8
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 7SCF54H12J
| ATC_prefix = A03
| ATC_prefix = A03
| ATC_suffix = AX04
| ATC_suffix = AX04
| PubChem = 40704
| PubChem = 40703
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank = DBSALT001130
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 37181
| smiles = CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)Cc4cc(c(cc4Br)OC)OC)C.[Br-]
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C26H41BrNO4.BrH/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27;/h15,17,19,21-22H,5-14,16,18H2,1-4H3;1H/q+1;/p-1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = IKGXLCMLVINENI-UHFFFAOYSA-M


<!--Chemical data-->
<!--Chemical data-->
| C=26 | H=41 | Br=1 | N=1 | O=4
| C=26 | H=41 | Br=2 | N=1 | O=4
| molecular_weight = 511.51 g/mol
}}
}}


'''Pinaverium bromide''' ([[International Nonproprietary Name|INN]]) is a medication used for [[functional gastrointestinal disorder]]s. It belongs to a drug group called [[antispasmodic]]s and acts as a [[calcium channel blocker]] in helping to restore the normal contraction process of the bowel. It is most effective when taken for a full course of treatment and is not designed for immediate symptom relief or sporadic, intermittent use.<ref>{{cite book | vauthors = | chapter = Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines [Internet]. | title = CADTH Rapid Response Reports | location = Ottawa (ON) | publisher = Canadian Agency for Drugs and Technologies in Health | date = November 2015 | pmid = 26985535 | chapter-url = https://www.ncbi.nlm.nih.gov/books/NBK350043/ }}</ref>
'''Pinaverium''' is a drug used for [[functional gastrointestinal disorder]]s. It acts as a [[calcium channel blocker]].


Pinaverium bromide was first registered in 1975 by [[Solvay_S.A.|Solvay Pharmaceuticals]] (now a division of [[Abbott Laboratories]]), and marketed globally using the brand names '''Dicetel''' and '''Eldicet'''. Generic pinaverium is available in South Korea under a trade name of '''Disten'''<ref>{{cite web | url = http://www.kmle.co.kr/viewDrug.php?m=%B6%F3%BD%C4&inx=26702&c=afdf17b8b3cde357bf3163dd78dbc00f | work = KMLE | title = Drug/Drug Information: Disten Tablet | language = ko}}</ref> and in Argentina as '''Nulite'''.<ref>{{Cite web | url=http://www.labdominguez.com.ar/es/productos/28-nulite |title = NULITE | work = Laboratorio Dominguez}}</ref>

==Indications==
It is indicated for the treatment and relief of symptoms associated with [[irritable bowel syndrome]] (IBS) including abdominal pain, bowel disturbances and intestinal discomfort; and treatment of symptoms related to functional disorders of biliary tract.<ref>{{Cite book|author=Abbott Laboratories |title=Dicetel Product Insert/Information Malaysia| date=Feb 2012 }}</ref>

==References==
{{Reflist}}


{{Drugs for functional gastrointestinal disorders}}
{{Drugs for functional gastrointestinal disorders}}
Line 46: Line 63:
[[Category:Quaternary ammonium compounds]]
[[Category:Quaternary ammonium compounds]]
[[Category:Morpholines]]
[[Category:Morpholines]]
[[Category:Drugs developed by AbbVie]]
[[Category:Phenol ethers]]
[[Category:Phenol ethers]]
[[Category:Ethers]]
[[Category:Ethers]]
[[Category:Organobromides]]
[[Category:Organobromides]]
[[Category:Methoxy compounds]]


{{gastrointestinal-drug-stub}}

[[hu:Pinaverin]]